MedPath
HSA Approval

VIRGAN EYE GEL 1.5 mg/g

SIN11778P

VIRGAN EYE GEL 1.5 mg/g

VIRGAN EYE GEL 1.5 mg/g

January 18, 2002

DCH AURIGA SINGAPORE

DCH AURIGA SINGAPORE

Regulatory Information

DCH AURIGA SINGAPORE

DCH AURIGA SINGAPORE

Therapeutic

Prescription Only

Formulation Information

OINTMENT

**3\. HOW TO USE VIRGAN 1.5 mg/g, eye gel** **Dosage** Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is 1 drop 3 to 5 times daily. **Use in children** The use of this eye gel in children before 18 years is not recommended. **Method of administration** This medicine is intended to be administered into the affected eye (ocular use). 1. Wash your hands thoroughly before using the product, 2. Gently squeeze the tube to release a drop into the affected eye, while looking upwards and pulling the lower eyelid down, 3. Close the tube after use. **Duration of treatment** The treatment should not usually exceed 21 days. **If you use more VIRGAN 1.5 mg/g, eye gel than you should** Continue your treatment as instructed by your doctor. Immediately contact your doctor or your pharmacist. **If you forget to use VIRGAN 1.5 mg/g, eye gel** Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this product, ask your doctor or pharmacist.

OPHTHALMIC

Medical Information

**1\. WHAT VIRGAN 1.5 mg/g, eye gel IS AND WHAT IT IS USED FOR** Pharmacotherapeutic class: antiinfectives – antivirals ATC code: S01AD09. VIRGAN is an eye gel containing an antiviral agent called ganciclovir. It is indicated in the treatment of certain superficial and viral eye infections (cornea).

**2\. WHAT YOU NEED TO KNOW BEFORE YOU USE VIRGAN 1.5 mg/g, eye gel** **DO NOT use VIRGAN 1.5 mg/g, eye gel** - if you are allergic to ganciclovir, aciclovir or any of the other ingredients of this medicine (listed in section 6 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). - during pregnancy and breast-feeding, unless instructed otherwise by your doctor. - in men and women of childbearing age not using a method of birth control. Moreover, men treated by VIRGAN are advised to use a local method of contraception (such as a condom) during treatment and for three months after the end of the treatment.

S01AD09

ganciclovir

Manufacturer Information

DCH AURIGA SINGAPORE

FARMILA-THEA FARMACEUTICI S.P.A

Active Ingredients

GANCICLOVIR

0.15g/ 100g

Ganciclovir

Documents

Package Inserts

Virgan Eye Gel PI.pdf

Approved: May 4, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

VIRGAN EYE GEL 1.5 mg/g - HSA Approval | MedPath